Tagged: ipo RSS Toggle Comment Threads | Keyboard Shortcuts

  • mayay 1:05 pm on August 4, 2014 Permalink
    Tags: bioblast, , biomed companies, drop, , , ipo, , , , ,   

    Three Israeli Biomed Companies See Share Price Drop After NASDAQ IPO 

    nasdaqAugust 4, 2014 | According to “Globes,” following their NASDAQ IPO’s, three Israeli biomed companies saw the value of their shares drop sharply. BioBlast‘s share lost 38 percent of its value, Macrocure‘s 25 percent and VBL Therapeutics 18 percent. The drop in prices corresponds to three percent dip in the NASDAQ biotechnology index last Thursday and Friday. VBL Therapeutics, a company developing breakthrough drugs for infectious diseases and cancer, raised $65 million at $12 a share, which dropped to $9.88 a share by the end of Friday. Macrocure, a company developing treatments for wounds, raised $53 million at $10 a share, but the share price dropped 25 percent down to $7.49 a share. BioBlast Pharma, a developer of drugs for rare diseases, saw shares valued at $11 a piece drop to $6.90, a 38 percent drop.

     
  • mayay 12:51 pm on August 3, 2014 Permalink
    Tags: 5.31 billion, , , , , ipo, , , ,   

    Mobileye Valued At $5.31B Following NYSE IPO 

    Report: Mobileye Planning IPO At A Company Value Of $5BAugust 3, 2014 | The developer of car accident prevention systems Mobileye raised $890 million in its New York Stock Exchange IPO on August 1, 2014 (Friday), putting the company value at $5.31 billion, a much higher amount than estimated. The current valuation makes Mobileye the Israeli company with the fifth highest market cap on Wall Street. The Mobileye warning system consists of a set of cameras and artificial vision technology that let the driver know when they are prone to an accident. Mobileye’s system issues warnings when a car strays out of its lane, tailgates the car in front of it and even when the vehicle gets too close to pedestrians and cyclists on the street. Mobileye has already sold its technology to more than 20 automobile manufactures, including General Motors and BMW, and their systems have already been installed in up to 3.3 million vehicles.

     
  • mayay 12:42 pm on August 3, 2014 Permalink
    Tags: 5.4 million shares, brain cancer, ipo, , , ,   

    VBL Therapeutics Announces Pricing Of NASDAQ IPO 

    vbltherapeuticsAugust 3, 2014 | Israeli biotech company VBL Therapeutics announced the pricing of its NASDAQ IPO. The company will sell 5,400,000 shares at $12.00 per share for a gross total of $64.8 million. In addition, VBL Therapeutics will grant underwriters 30 days to purchase up to 810,000 additional shares at the same price in order to cover over-allotments. The shares began trading on NASDAQ on July 31, 2014 under the ticker symbol VBLX with the offering due to close on August 5, 2014. VBL Therapeutics was founded in 2000 in Tel Aviv, Israel and is currently working towards developing a cure for brain cancer, which it hopes to begin Phase III clinical trials on in 2015.

     
  • mayay 12:30 pm on August 3, 2014 Permalink
    Tags: bioblast pharma, , , ipo, , orpn, , ultra-rare genetic diseases   

    BioBlast Pharma Raises $37M In NASDAQ IPO 

    bioblast_logo31August 3, 2014 | Israeli pharmaceutical company BioBlast announced that it raised $37 million in its NASDAQ IPO last week. The company priced 3,200,000 ordinary shares at $11 per share making gross proceeds of $35.2 million. The company also granted the underwriters 30 days to purchase up to 480,000 additional shares. BioBlasts offering, trading under the ticker ORPN is expected to close on August 5, 2014, subject to customary closings. BioBlast is an Israeli clinical stage biotechnology company founded in 2012 developing treatments for rare and ultra-rare genetic diseases.

     
  • mayay 12:45 pm on July 31, 2014 Permalink
    Tags: $54million, cureXcell, , ipo, , nsadaq, , , ,   

    Macrocure Raises $54M In NASDAQ IPO 

    macrocureJuly 31, 2014 | The regenerative medicine developer Macrocure raised $54 million in its NASDAQ IPO, offering up 5.35 million shares at $10 a pop. The share price was below the average of between $13-15 that company had originally planned. The Macrocure shares will trade under the ticker “MCUR” with the company granting underwriters 30 days to purchase up to 802, 500 additional sales before the offering closes out on August 5th. Credit Suisse Securities (USA) and Jefferies LLC are the joint book-running managers for the offering, with Nomura Securities International and Oppenheimer & Co. acting as co-managers. Macrocure has developed a system for treating hard-to-heal wounds using white blood cells taken from donor blood, a product called CureXcell.

     
  • mayay 12:32 pm on July 30, 2014 Permalink
    Tags: $600 million, , collision prevention technology, , , ipo, , , new york stock exchange, , , ,   

    Mobileye Set To Raise $600M Following NYSE IPO 

    Report: Mobileye Planning IPO At A Company Value Of $5BJuly 30, 2014 | The Israeli collision avoidance technology developer Mobileye increased the estimates for the amount of money it is set to raise when it goes public this week on the New York Stock Exchange (NYSE). The company is now filing with the SEC that it will raise over $600 million, offering up 27.8 million shares ranging between $21 to $23. The newest price estimates, about 22 percent higher than was previously expected, is expected to put the company value at a total of $5.2 billion, according to “Globes.” Founded in 1999 and headquartered in The Netherlands, Mobileye provides camera-based collision prevention technology for automobiles.

     
  • mayay 12:58 pm on July 28, 2014 Permalink
    Tags: , ipo, mapi pharma, , , , , prospectus   

    Mapi Pharma Publishes Revised $20M Prospectus For IPO 

    logo-mapiJuly 28, 2014 | Mapi Pharma, which was scheduled to complete a $37 million financing round by the end of last week, has published a revised prospectus for $20 million. As a result the company value for the IPO was lowered to $120 million after money. Aegis Capital is leading the IPO along with Chardan Capital as the second underwriter. Mapi Pharma is headed by CEO Ehud Marom and manufactures complicated-to-procedure raw materials for generic drugs and has a technological platform for delayed drug release.

     
  • mayay 12:21 pm on July 23, 2014 Permalink
    Tags: , , , , ipo, , , ,   

    Mobileye IPO To Be Valued At $3.8B 

    Report: Mobileye Planning IPO At A Company Value Of $5BJuly 23, 2014 | According to a “Globes” report, the Mobileye initial public offering on Wall Street will be valued at approximately $3.8 billion after money. The original prospectus was for a valuation between $3.5-5 billion, making the actual valuation at the lower end of estimates. The company will offer 8.325 million shares at a price of $17-19 per share. The offering will most likely take place in two weeks, when the stock will be traded under the ticker MBLY on the New York Stock Exchange. Mobileye was founded in 1999 and has developed a camera-based system to mount on vehicles in order to aid in collision prevention.

     
  • mayay 12:33 pm on July 21, 2014 Permalink
    Tags: , ipo, , , , , , triple in revenue,   

    Mobileye’s Revenue Triples Before Wall Street IPO 

    Report: Mobileye Planning IPO At A Company Value Of $5BJuly 21, 2014 | According to a “Globes” report, Mobileye collision prevention solutions provider has updated is Wall Street IPO filing with first quarter 2014 results and a list of current shareholders. Mobileye expects the offering at a company value of $3.5-5 billion, especially since the revenue keeps rolling in for the company. “Globes” reports that Mobileye’s first quarter revenue rose by 204% from the corresponding quarter due to a spike in sales to automakers like GM, Nissan, Ford and Volvo, among others. Mobileye is an Israeli startup that has developed a system based on camera and artificial vision technology for automobiles with the purpose of preventing accidents.

     
  • mayay 2:03 pm on July 9, 2014 Permalink
    Tags: digital ad, ipo, , , pence   

    Matomy Raises $70M In London Public Offering 

    matomyJuly 9, 2014 | Matomy Media Group raised a total of $70 million following their initial public offering (IPO) on the London Stock Exchange. Following the offering, the digital ad company was valued at $347 million. The offering closed just after one day at a price of 227 pence ($3.89), with Matomy offering up 21 percent of the company to new investors.

    Matomy was founded in 2007 by Ofer Druker and is controlled by Ilan Shiloach and specializes in digital and mobile advertising.

     
c
compose new post
j
next post/next comment
k
previous post/previous comment
r
reply
e
edit
o
show/hide comments
t
go to top
l
go to login
h
show/hide help
shift + esc
cancel